Daratumumab is a monoclonal antibody targeting CD38, a glycoprotein expressed at high levels on multiple myeloma cells and other hematopoietic cells. While effective in inducing apoptosis and immune-mediated cytotoxicity via mechanisms like antibody-dependent cellular phagocytosis (ADCP), complement-dependent cytotoxicity (CDC), and antibody-dependent cellular cytotoxicity (ADCC), the repeated administration of daratumumab can lead to the development of anti-drug antibodies (ADAs), including neutralizing and non-neutralizing types.
Monitoring for anti-daratumumab antibodies is essential in both clinical and research settings to evaluate immunogenicity, drug efficacy, and patient safety. Neutralizing antibodies (NAbs) can impair therapeutic response by inhibiting the drug’s binding to CD38 or its downstream effects. Non-neutralizing ADAs, while not directly affecting the drug’s pharmacodynamics, may still influence pharmacokinetics or contribute to hypersensitivity reactions.
In research settings, tracking ADA formation aids in the optimization of daratumumab regimens and informs the design of next-generation CD38-targeting therapies. Clinically, early detection of anti-daratumumab antibodies through validated immunogenicity assays supports individualized treatment planning, minimizes adverse effects, and enhances overall therapeutic outcomes in patients with multiple myeloma.
This product is manufactured in Turkey by Matriks Biotek.